Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | YES1 | P07947 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881345 | 0.92 | BRAF (0.58) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4882288 | 0.86 | BRAF (0.65) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4888801 | 0.85 | BRAF (0.58) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4885458 | 0.81 | MAPK14 (0.79) | MAPK14 | |
| SCHEMBL4884396 | 0.81 | BRAF (0.58) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4881183 | 0.81 | BRAF (0.57) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4878902 | 0.81 | MAPK14 (0.68) | BRAFRAF1YES1MAPK14 | |
| SCHEMBL4882595 | 0.81 | MAPK14 (0.74) | BRAFRAF1YES1MAPK14 | |
| SCHEMBL4889064 | 0.81 | BRAF (0.57) | BRAFRAF1YES1MAPK14CYP2C9 | |
| SCHEMBL4886681 | 0.80 | BRAF (0.56) | BRAFRAF1YES1MAPK14CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | BRAF 1/4885RAF1 3/4885YES1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.